Ironwood Historical Financial Ratios

IRWD Stock

USD 1.41 0.05 3.42%

Ironwood Pharmaceuticals is lately reporting on over 110 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Inventory Turnover of 0.97 or Net Income Per Share of 0.86 will help investors to properly organize and evaluate Ironwood Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

About Ironwood Financial Ratios Analysis

Ironwood PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Ironwood Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Ironwood financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Ironwood Pharmaceuticals history.

Ironwood Pharmaceuticals Financial Ratios Chart

At present, Ironwood Pharmaceuticals' Days Of Inventory On Hand is projected to decrease significantly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 12.65, whereas PTB Ratio is projected to grow to (4.39).

Price To Sales Ratio Inventory Turnover Days Of Inventory On Hand Payables Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Ironwood Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ironwood Pharmaceuticals sales, a figure that is much harder to manipulate than other Ironwood Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Ironwood Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Days Of Inventory On Hand is projected to decrease significantly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 12.65, whereas PTB Ratio is projected to grow to (4.39).

	2022	2024	2025 (projected)
Payables Turnover	2.94	12.04	12.65
Days Of Inventory On Hand	321.76	370.02	560.14

Payables Turnover Days Of Inventory On Hand

Ironwood Pharmaceuticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Capex To Depreciation	Pb Ratio	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Current Ratio	Receivables Turnover	Debt To Equity	Revenue Per Share
Price To Sales Ratio		-0.09	0.12	-0.09	0.04	-0.17	-0.02	0.55	-0.26	-0.18	-0.02	0.05	-0.13	-0.04	0.16	-0.01	-0.05	-0.11	0.08	-0.09	-0.05	0.33	-0.09	-0.11	-0.08	-0.57
Ptb Ratio	-0.09		0.01	1.0	0.22	0.23	-0.04	-0.17	-0.26	-0.27	0.1	-0.09	-0.23	-0.03	0.22	-0.86	-0.29	0.09	0.19	-0.24	-0.04	0.46	-0.01	-0.08	0.99	-0.04
Capex To Depreciation	0.12	0.01		0.01	0.2	-0.09	-0.01	0.05	-0.31	-0.37	0.0	-0.95	-0.02	-0.08	-0.1	-0.04	-0.37	-0.22	0.2	-0.01	-0.03	0.34	-0.11	-0.01	0.01	-0.07
Pb Ratio	-0.09	1.0	0.01		0.22	0.23	-0.04	-0.17	-0.26	-0.27	0.1	-0.09	-0.23	-0.03	0.22	-0.86	-0.29	0.09	0.19	-0.24	-0.04	0.46	-0.01	-0.08	0.99	-0.04
Roic	0.04	0.22	0.2	0.22		0.14	0.51	0.0	-0.81	0.02	-0.09	-0.13	0.14	0.14	0.73	-0.3	0.01	-0.21	0.99	0.13	0.34	0.21	0.5	0.1	0.26	0.01
Inventory Turnover	-0.17	0.23	-0.09	0.23	0.14		-0.08	-0.4	-0.09	0.48	0.23	0.2	0.57	-0.13	-0.15	-0.23	0.46	-0.59	0.14	0.56	-0.12	-0.18	-0.08	-0.21	0.23	0.35
Net Income Per Share	-0.02	-0.04	-0.01	-0.04	0.51	-0.08		-0.03	-0.2	0.1	0.04	0.02	0.08	-0.05	0.25	0.1	0.09	0.04	0.4	0.08	0.98	-0.22	0.31	-0.02	0.0	0.1
Days Of Inventory On Hand	0.55	-0.17	0.05	-0.17	0.0	-0.4	-0.03		-0.33	-0.23	-0.81	0.06	-0.23	-0.09	0.27	0.02	-0.15	-0.01	0.05	-0.2	-0.05	0.48	-0.21	0.74	-0.21	-0.62
Payables Turnover	-0.26	-0.26	-0.31	-0.26	-0.81	-0.09	-0.2	-0.33		0.27	0.31	0.23	0.1	-0.23	-0.65	0.51	0.26	0.18	-0.82	0.1	-0.05	-0.63	-0.19	-0.3	-0.26	0.44
Pocfratio	-0.18	-0.27	-0.37	-0.27	0.02	0.48	0.1	-0.23	0.27		0.14	0.57	0.93	-0.09	-0.06	0.18	0.99	-0.7	0.03	0.92	0.09	-0.48	0.14	-0.12	-0.27	0.39
Interest Coverage	-0.02	0.1	0.0	0.1	-0.09	0.23	0.04	-0.81	0.31	0.14		-0.04	0.13	0.06	-0.26	-0.03	0.12	0.04	-0.13	0.13	0.08	-0.4	0.2	-0.99	0.14	0.32
Capex To Operating Cash Flow	0.05	-0.09	-0.95	-0.09	-0.13	0.2	0.02	0.06	0.23	0.57	-0.04		0.26	0.05	0.14	0.05	0.59	-0.05	-0.12	0.26	0.02	-0.31	0.09	0.03	-0.09	0.02
Pfcf Ratio	-0.13	-0.23	-0.02	-0.23	0.14	0.57	0.08	-0.23	0.1	0.93	0.13	0.26		-0.09	-0.09	0.11	0.92	-0.89	0.15	1.0	0.06	-0.32	0.07	-0.12	-0.23	0.35
Days Payables Outstanding	-0.04	-0.03	-0.08	-0.03	0.14	-0.13	-0.05	-0.09	-0.23	-0.09	0.06	0.05	-0.09		0.05	-0.05	-0.1	0.02	0.13	-0.09	-0.07	0.28	0.0	-0.07	0.01	-0.21
Income Quality	0.16	0.22	-0.1	0.22	0.73	-0.15	0.25	0.27	-0.65	-0.06	-0.26	0.14	-0.09	0.05		-0.34	-0.06	0.08	0.74	-0.09	0.12	0.3	0.69	0.27	0.24	-0.25
Roe	-0.01	-0.86	-0.04	-0.86	-0.3	-0.23	0.1	0.02	0.51	0.18	-0.03	0.05	0.11	-0.05	-0.34		0.19	0.1	-0.29	0.11	0.14	-0.66	0.0	0.01	-0.83	0.33
Ev To Operating Cash Flow	-0.05	-0.29	-0.37	-0.29	0.01	0.46	0.09	-0.15	0.26	0.99	0.12	0.59	0.92	-0.1	-0.06	0.19		-0.72	0.02	0.92	0.09	-0.45	0.11	-0.12	-0.29	0.32
Pe Ratio	-0.11	0.09	-0.22	0.09	-0.21	-0.59	0.04	-0.01	0.18	-0.7	0.04	-0.05	-0.89	0.02	0.08	0.1	-0.72		-0.24	-0.9	0.08	-0.08	0.12	-0.02	0.1	-0.06
Return On Tangible Assets	0.08	0.19	0.2	0.19	0.99	0.14	0.4	0.05	-0.82	0.03	-0.13	-0.12	0.15	0.13	0.74	-0.29	0.02	-0.24		0.15	0.22	0.23	0.5	0.13	0.23	0.0
Ev To Free Cash Flow	-0.09	-0.24	-0.01	-0.24	0.13	0.56	0.08	-0.2	0.1	0.92	0.13	0.26	1.0	-0.09	-0.09	0.11	0.92	-0.9	0.15		0.06	-0.31	0.07	-0.12	-0.24	0.33
Earnings Yield	-0.05	-0.04	-0.03	-0.04	0.34	-0.12	0.98	-0.05	-0.05	0.09	0.08	0.02	0.06	-0.07	0.12	0.14	0.09	0.08	0.22	0.06		-0.25	0.22	-0.05	-0.01	0.08
Intangibles To Total Assets	0.33	0.46	0.34	0.46	0.21	-0.18	-0.22	0.48	-0.63	-0.48	-0.4	-0.31	-0.32	0.28	0.3	-0.66	-0.45	-0.08	0.23	-0.31	-0.25		-0.26	0.36	0.42	-0.77
Current Ratio	-0.09	-0.01	-0.11	-0.01	0.5	-0.08	0.31	-0.21	-0.19	0.14	0.2	0.09	0.07	0.0	0.69	0.0	0.11	0.12	0.5	0.07	0.22	-0.26		-0.17	0.03	0.29
Receivables Turnover	-0.11	-0.08	-0.01	-0.08	0.1	-0.21	-0.02	0.74	-0.3	-0.12	-0.99	0.03	-0.12	-0.07	0.27	0.01	-0.12	-0.02	0.13	-0.12	-0.05	0.36	-0.17		-0.12	-0.27
Debt To Equity	-0.08	0.99	0.01	0.99	0.26	0.23	0.0	-0.21	-0.26	-0.27	0.14	-0.09	-0.23	0.01	0.24	-0.83	-0.29	0.1	0.23	-0.24	-0.01	0.42	0.03	-0.12		0.0
Revenue Per Share	-0.57	-0.04	-0.07	-0.04	0.01	0.35	0.1	-0.62	0.44	0.39	0.32	0.02	0.35	-0.21	-0.25	0.33	0.32	-0.06	0.0	0.33	0.08	-0.77	0.29	-0.27	0.0

Click cells to compare fundamentals

Ironwood Pharmaceuticals Account Relationship Matchups

Ironwood Pharmaceuticals fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	4.85	4.66	4.57	4.02	2.01	1.91
Ptb Ratio	28.99	3.12	2.93	(5.13)	(4.62)	(4.39)
Capex To Depreciation	1.29	0.52	0.17	0.0959	0.2	0.19
Pb Ratio	28.99	3.12	2.93	(5.13)	(4.62)	(4.39)
Roic	0.26	0.56	0.16	(2.59)	(2.33)	(2.21)
Net Income Per Share	0.67	3.26	1.13	(6.45)	0.82	0.86
Payables Turnover	4.74	1.63	2.94	13.38	12.04	12.65
Research And Ddevelopement To Revenue	0.23	0.17	0.11	0.26	0.31	0.3
Pocfratio	10.76	7.22	6.99	9.69	8.72	9.16
Interest Coverage	4.85	7.46	32.95	(43.71)	(2.87)	(3.01)
Capex To Operating Cash Flow	0.0109	0.001012	4.97E-4	0.001488	0.001339	0.001406
Pfcf Ratio	10.87	7.23	6.99	9.71	8.74	8.3
Days Payables Outstanding	76.93	224.08	124.33	27.27	31.37	29.8
Income Quality	0.25	0.5	1.59	1.56	(0.18)	(0.16)
Roe	1.7	0.87	0.27	2.89	2.6	2.73
Ev To Operating Cash Flow	11.3	6.67	6.11	13.09	11.78	12.37
Pe Ratio	17.1	3.58	10.93	(1.77)	5.41	5.68
Return On Tangible Assets	0.19	0.46	0.16	(2.14)	(2.47)	(2.34)
Ev To Free Cash Flow	11.42	6.68	6.11	13.11	11.8	11.21
Earnings Yield	0.0585	0.28	0.0915	(0.56)	0.18	0.19
Intangibles To Total Assets	0.001404	(0.0217)	(0.0137)	0.007816	0.008989	0.008539
Current Ratio	15.16	4.61	30.58	0.84	0.76	0.72
Debt To Equity	7.24	0.79	0.64	(2.07)	(1.86)	(1.77)
Revenue Per Share	2.44	2.55	2.66	2.85	2.2	1.5
Debt To Assets	0.81	0.42	0.38	1.52	1.37	1.44
Days Sales Outstanding	114.65	100.6	102.64	106.45	122.42	142.02
Book Value Per Share	0.39	3.73	4.23	(2.23)	(2.01)	(2.11)
Free Cash Flow Yield	0.001703	0.092	0.14	0.1	0.0927	0.0973
Operating Cash Flow Per Share	0.0687	1.06	1.61	1.77	1.18	1.12
Stock Based Compensation To Revenue	0.08	0.0539	0.0659	0.0723	0.0831	0.079
Ev To Sales	4.9	4.22	4.07	5.42	6.24	5.93
Free Cash Flow Per Share	1.05	1.61	1.77	1.18	1.06	1.11
Capex To Revenue	0.004729	6.4E-4	3.31E-4	6.17E-4	7.09E-4	6.74E-4
Cash Per Share	2.27	3.82	4.25	0.59	0.68	0.65
Net Debt To E B I T D A	0.64	(0.62)	(0.92)	(0.67)	(0.78)	(0.81)
Tangible Book Value Per Share	0.39	3.89	4.32	(2.25)	(2.03)	(2.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:

How To Invest In Ironwood

Details

Is Ironwood Stock a good investment?

Details

What is Ironwood Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.77)

Earnings Share

0.01

Revenue Per Share

1.938

Quarterly Revenue Growth

(0.23)

Return On Assets

0.1481

The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Ptb Ratio
Capex To Depreciation	Pb Ratio
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue	Pocfratio
Interest Coverage	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Income Quality	Roe
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Current Ratio	Receivables Turnover
Debt To Equity	Revenue Per Share
Debt To Assets	Dividend Yield
Days Sales Outstanding	Book Value Per Share
Free Cash Flow Yield	Invested Capital
Operating Cash Flow Per Share	Average Payables
Stock Based Compensation To Revenue	Ev To Sales
Free Cash Flow Per Share	Average Inventory
Capex To Revenue	Cash Per Share
Payout Ratio	Net Current Asset Value
Tangible Asset Value	Net Debt To E B I T D A
Tangible Book Value Per Share	Shareholders Equity Per Share
Capex Per Share	Graham Net Net
Average Receivables	Interest Debt Per Share
Enterprise Value Over E B I T D A	Graham Number
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity	Operating Cycle
Dividend Payout Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Sales Outstanding
Enterprise Value Multiple

Ironwood Historical Financial Ratios

About Ironwood Financial Ratios Analysis

Ironwood Pharmaceuticals Financial Ratios Chart

Price To Sales Ratio

Inventory Turnover

Payables Turnover

Ironwood Pharmaceuticals fundamentals Correlations

Ironwood Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ironwood Pharmaceuticals fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Ev To Free Cash Flow	+ 1.0	Pfcf Ratio
Debt To Equity	+ 0.99	Ptb Ratio
Debt To Equity	+ 0.99	Pb Ratio
Return On Tangible Assets	+ 0.99	Roic
Ev To Operating Cash Flow	+ 0.99	Pocfratio

Receivables Turnover	- 0.99	Interest Coverage
Capex To Operating Cash Flow	- 0.95	Capex To Depreciation
Ev To Free Cash Flow	- 0.9	Pe Ratio
Pe Ratio	- 0.89	Pfcf Ratio
Roe	- 0.86	Pb Ratio
Roe	- 0.86	Ptb Ratio